Cardiovascular Therapies and Associated Glucose Homeostasis Implications Across the Dysglycemia Continuum

被引:38
作者
Cooper-DeHoff, Rhonda M. [1 ]
Pacanowski, Michael A. [2 ,3 ]
Pepine, Carl J. [1 ]
机构
[1] Univ Florida, Coll Med, Div Cardiovasc Med, Gainesville, FL 32610 USA
[2] Univ Florida, Dept Pharm Practice, Gainesville, FL 32610 USA
[3] Univ Florida, Ctr Pharmacogenom, Coll Pharm, Gainesville, FL 32610 USA
关键词
IMPAIRED FASTING GLUCOSE; LIPID-LOWERING TREATMENT; ANGIOTENSIN RECEPTOR BLOCKERS; HEALED MYOCARDIAL-INFARCTION; TYPE-2; DIABETES-MELLITUS; CORONARY-ARTERY-DISEASE; METABOLIC SYNDROME; INSULIN-RESISTANCE; CLINICAL-OUTCOMES; ANTIHYPERTENSIVE TREATMENT;
D O I
10.1016/j.jacc.2008.10.037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Certain cardiovascular drugs have adverse effects on glucose homeostasis, which may lead to important long-term implications for increased risks of adverse outcomes. Thiazide diuretics, niacin, and beta-adrenergic blockers impair glucose homeostasis. However, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have demonstrated beneficial metabolic effects. The newer vasodilating beta-blocking agents and calcium antagonists appear to be metabolically neutral. These considerations, in addition to meticulous attention to blood pressure control and lifestyle changes, have the potential to beneficially modify glycemia and long-term risks. These considerations have particular importance in younger patients who may also have pre-diabetes or the metabolic syndrome and who are likely to require therapy over the course of decades. (J Am Coll Cardiol 2009;53:S28-34) (C) 2009 by the American College of Cardiology Foundation
引用
收藏
页码:S28 / S34
页数:7
相关论文
共 75 条
[1]  
*AACE HYP TASK FOR, 2006, ENDOCR PRACT, V12, P193
[2]   Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes - A meta-analysis of randomized clinical trials [J].
Abuissa, H ;
Jones, PG ;
Marso, SP ;
O'Keefe, JH .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (05) :821-826
[3]   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].
Adler, AI ;
Stratton, IM ;
Neil, HAW ;
Yudkin, JS ;
Matthews, DR ;
Cull, CA ;
Wright, AD ;
Turner, RC ;
Holman, RR .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419
[4]   Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial population [J].
Aksnes, Tonje A. ;
Kjeldsen, Sverre E. ;
Rostrup, Morten ;
Omvik, Per ;
Hua, Tsushung A. ;
Julius, Stevo .
HYPERTENSION, 2007, 50 (03) :467-473
[5]   New onset diabetes during antihypertensive therapy [J].
Alderman, Michael H. .
AMERICAN JOURNAL OF HYPERTENSION, 2008, 21 (05) :493-499
[6]  
[Anonymous], HEART DIS STROK STAT
[7]  
[Anonymous], 2005, NAT DIAB FACT SHEET
[8]  
[Anonymous], DIAB COST CALC
[9]  
Antman EM, 2008, J AM COLL CARDIOL, V51, P2028, DOI [10.1016/j.jacc.2008.04.002, 10.1016/j.jacc.2007.10.001]
[10]   Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial [J].
Bakris, GL ;
Fonseca, V ;
Katholi, RE ;
McGill, JB ;
Messerli, FH ;
Phillips, RA ;
Raskin, P ;
Wright, JT ;
Oakes, R ;
Lukas, MA ;
Anderson, KM ;
Bell, DSH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18) :2227-2236